Developer docs
API playgroundTry for free, no card

Search company profiles

N=1 Collaborative

Full company profile

uuid000yrbz

Namestring
N=1 Collaborative
Legal namestring
N=1 Collaborative
Company typeenum
Private
Founded yearint
2021
Descriptiontext

N=1 Collaborative (N1C) is a 501(c)-style nonprofit professional society founded in 2021 and headquartered in Somerville, Massachusetts, that serves as the convening body for the individualized genomic medicine field targeting ultra-rare and neurogenetic diseases. The organization operates the Connections platform as its central digital hub, complemented by specialized tools and programs including the Gene Registry (catalog of individualized therapy programs, marketed gene therapies, and assessed variants), N1C VARIANT (eligibility assessment tool for antisense oligonucleotide treatment), the Donated Resource Center, a Seminar Series, the 'Fireside Chats in Individualized Medicine' podcast, eight cross-sector workgroups (Patient Identification, Preclinical Design, Manufacturing, Institutional Implementation, Clinical Outcomes, Regulatory, Data Coordination, and Access & Funding), and an Annual Meeting. Founding support came from the Oligonucleotide Therapeutics Society N-of-1+ Taskforce and the Chan Zuckerberg Initiative, with a founding committee led by Dr. Tim Yu (designer of milasen, the first individualized ASO) and Julia Vitarello (Mila's mother).

N1C monetizes through three streams: (1) recurring membership fees that unlock exclusive Connections spaces, patient and research community engagement, virtual streaming of the Annual Meeting, and recording access; (2) sponsorships and the structured Corporate Alliance program, which let mission-aligned companies co-create shared infrastructure; and (3) tiered Annual Meeting registration ($295 industry, $180 academic/nonprofit, $120 trainee, free for parents and families). Membership pricing is gated behind platform registration and is not publicly disclosed. Customer segments span five stakeholder groups — researchers and drug developers, clinicians, patients/families/advocates (primary), plus industry/corporate partners and regulators (secondary) — with no single segment generating concentrated revenue.

The organization has facilitated treatment of more than 80 patients with over 30 individualized ASOs since the milasen precedent, and in 2025 the first personalized CRISPR-based therapy was designed, approved, and delivered in six months. Strategic positioning has been reinforced by participation in the One to Millions global public-private initiative (with Critical Path Institute, n-Lorem Foundation, Mila's Miracle Foundation, and Boston Children's Hospital, announced March 2026) and active alignment with the FDA's Plausible Mechanism Framework and the UK's rare therapies guidance. Nicole Nolen, the organization's first hire in 2022, was appointed Executive Director in June 2026, marking a transition from founder-led to executive-managed operations.

Short descriptiontext

N=1 Collaborative is a 2021-founded nonprofit professional society convening researchers, clinicians, patients, regulators, and industry to advance individualized genomic medicines for ultra-rare diseases via its Connections platform, Gene Registry, workgroups, and annual meeting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSomerville, United States
HQ citystring
Somerville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
individualized genomic medicine, antisense oligonucleotide therapies, rare disease therapeutics, precision medicine collaboration, community convening platform
Industry1 code
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
NAICS code1 code
  • Professional Organizations81392
SIC code1 code
  • Services-Membership Organizations8600
Product category
Individualized Medicine Professional Society
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Membership Fees
TypeSubscription Recurring
Description

N1C membership provides access to exclusive platform spaces, patient and research community engagement, virtual streaming for annual meetings, recording access, and direct messaging. Membership directly supports the collective mission of advancing individualized medicines.

n1collaborative.org
2Sponsorships
TypeSubscription Recurring
Description

Mission-aligned organizations sponsor N1C programs including the Connections platform, annual meetings, and seminar series. Sponsorship supports N1C's ability to convene stakeholders, develop shared resources, and advance infrastructure for individualized medicine.

n1collaborative.org
3Conference Registration
TypeOne Time License
Description

Annual meeting generates revenue through tiered registration fees: Industry ($295), Academic & Nonprofit ($180), Trainee ($120), with Parents & Families attending free.

n1collaborative.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details4 tiers
1Industry registration for 2026 Annual Meeting
ModelOtherBilling cadenceOne time
Notes

$295 per attendee for industry representatives attending the October 10, 2026 Annual Meeting in Denver, CO.

n1collaborative.org
2Academic & Nonprofit registration for 2026 Annual Meeting
ModelOtherBilling cadenceOne time
Notes

$180 per attendee for academic and nonprofit representatives.

n1collaborative.org
3Trainee registration for 2026 Annual Meeting
ModelOtherBilling cadenceOne time
Notes

$120 per attendee for graduate students, postdoctoral fellows, clinical trainees, and other early-career researchers.

n1collaborative.org
4Parents & Families registration for 2026 Annual Meeting
ModelOtherBilling cadenceOne time
Notes

Free admission for patients and families to the Annual Meeting.

n1collaborative.org
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

N=1 Collaborative (N1C) is a global nonprofit professional society and convening organization that serves as the professional home for interventional genetics and individualized medicine for ultra-rare diseases. It operates the Connections virtual community platform and delivers programs including eight multidisciplinary workgroups, a seminar series, a podcast, an annual meeting, the Gene Registry data resource, the Donated Resource Center, and the N1C VARIANT eligibility assessment tool, building shared infrastructure across knowledge, resources, and data for the individualized medicine ecosystem.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than 80 patients treated with over 30 different individualized ASOs - demonstrating the field's progression from proof-of-concept to clinical reality
+2 more records
Product overview1 text field

N=1 Collaborative (N1C) is a global community organization serving as the professional home for interventional genetics. Rather than a unified software product, N1C operates as a platform-plus-programs organization offering the Connections community platform as its central hub, complemented by specialized tools (N1C VARIANT for eligibility assessment, Gene Registry for therapy programs), resource programs (Donated Resource Center), educational programming (Seminar Series, Podcast), collaborative workgroups (eight cross-sector groups), and an Annual Meeting. The portfolio is held together by the Connections platform, which serves as the primary engagement and resource-sharing portal for the individualized medicine ecosystem.

Product and service8 records
1Connections Platform
CategoryCommunity Platform
Description

N1C's virtual community platform for open discussion, resource sharing, collaboration, and problem solving among researchers, clinicians, patients, advocates, and industry partners developing individualized genomic medicines.

2N1C VARIANT
CategoryAssessment Tool
Description

Variant Assessments Towards Eligibility for Antisense Oligonucleotide Treatment - tools and guidance to support eligibility assessment for individualized therapies, representing a step toward standardized approaches to evaluating treatment eligibility.

3Gene Registry
CategoryData Resource
Description

Global catalog of individualized therapy programs, marketed gene therapies, and assessed variants designed to increase visibility and coordination across efforts, connecting researchers, clinicians, and patient communities.

4Donated Resource Center
CategoryResource Program
Description

Mobilizes in-kind goods and services to support individualized therapy efforts for patients with urgent needs by coordinating contributions across the ecosystem.

5Fireside Chats in Individualized Medicine
CategoryPodcast
Description

Podcast featuring conversations with leaders and emerging voices across the individualized medicine ecosystem, exploring technical strategy and evolving approaches in interventional genetics.

6N1C Workgroups
CategoryCollaborative Program
Description

Eight multidisciplinary workgroups (Patient Identification, Preclinical Design, Manufacturing, Institutional Implementation, Clinical Outcomes, Regulatory, Data Coordination, and Access & Funding) that develop practical tools and standards including consensus guidelines, publications, and illustrated examples.

7Seminar Series
CategoryEducational Program
Description

Ongoing virtual sessions bringing together experts across research, clinical care, and patient advocacy, covering technical insights, case studies, lessons learned, and systems-level challenges.

8N1C Annual Meeting 2026
CategoryConference
Description

Annual conference titled 'Individual Journeys, Shared Discoveries: Partnering for Progress in Individualized Medicine' held October 10, 2026 in Denver, CO, bringing together the rare disease and individualized medicine community for shared learning and collaboration.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

C-Path and N1C are founding partners in the One to Millions global public-private initiative to enable scalable development of advanced individualized therapies. The initiative leverages C-Path's regulatory-grade centralized data platform to support evidence generation, regulatory decision-making, and scalable development pathways for ASOs, gene therapies, RNA-based treatments, and genome editing for ultra-rare diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

n-Lorem Foundation is a founding member of the One to Millions initiative alongside N1C and C-Path. The foundation focuses on developing individualized antisense oligonucleotide therapies for patients with nano-rare genetic diseases, providing experimental medicines at no cost.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

Mila's Miracle Foundation is a founding member of the One to Millions initiative. Founded by Julia Vitarello (Mila's mother), the foundation advocates for and supports the development of individualized medicines for ultra-rare diseases, inspired by the milasen case that pioneered the field.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

Boston Children's Hospital is a participant in the One to Millions initiative, contributing clinical expertise and research capabilities to the effort to accelerate individualized therapy development for ultra-rare diseases.

Strategic tierCoreTypeOthersAnnounced on2026-03-26
Description

The FDA provides regulatory framework support through initiatives including the Plausible Mechanism Framework and Rare Disease Evidence Principles. These frameworks enable scalable development pathways for individualized therapies and are referenced in the One to Millions initiative. FDA's 2021 individualized ASO guidance established foundational regulatory pathways.

Strategic tierFoundingTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

The Oligonucleotide Therapeutics Society's N-of-1+ Taskforce provided founding support for N1C's creation in 2021. This scientific society brought together leaders who helped establish N1C as the professional home for the individualized medicine field.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest US rare disease umbrella organization serving patients, advocacy groups, and industry. Comparable as a broad convening and advocacy organization covering rare diseases, though NORD operates at a much larger scale and addresses a wider scope than N1C's individualized-medicine focus.

TypeBroad incumbent
Description

Long-established nonprofit advancing genetic health through data platforms (including Platform for Engaging Everyone Responsibly, or PEER) and a network of disease advocacy organizations. Comparable as a community-and-data infrastructure builder for genetic and rare disease communities.

TypeBroad incumbent
Description

Advocacy and policy organization for the rare disease community, focused on accelerating science, policy, and regulatory pathways. Comparable as a US-based rare disease ecosystem convener engaging FDA, NIH, and Congress on drug development issues parallel to N1C's regulatory work.

TypeDirect peer
Description

Founding One to Millions partner. Founded by Julia Vitarello (also an N1C founder), the foundation is anchored on the milasen case that pioneered individualized ASOs and advocates for ultra-rare patient access — closely aligned with N1C's mission and leadership.

TypeDirect peer
Description

Co-founding partner of One to Millions with N1C. C-Path provides regulatory-grade data infrastructure and works across multiple rare disease consortia, making it the closest peer in terms of public-private convening and regulatory science infrastructure for individualized therapies.

TypeEmerging player
Description

CZI's Rare As One Network funds rare disease patient-led organizations to accelerate research and treatments. Comparable as a CZI-backed ecosystem builder in rare disease; CZI also funded N1C's founding, making it both a funder and a parallel community-building initiative.

7FAST (Foundation for Angelman Syndrome Therapeutics)
TypeRegional player
Description

Patient-founded research foundation focused on a single ultra-rare disease. Comparable in mission orientation (patient-driven infrastructure for an ultra-rare condition advancing individualized therapeutics) but operates with a different scale and disease-specific scope.

TypeBroad incumbent
Description

Cross-stakeholder coalition advancing the adoption of personalized medicine across policy, clinical practice, and industry. Comparable to N1C as a convening platform for personalized medicine, but operates at a broader policy level across all personalized medicine rather than focusing on individualized n-of-1 therapies.

TypeDirect peer
Description

Founding partner in the One to Millions initiative and core collaborator with N1C. n-Lorem develops individualized ASO therapies for nano-rare patients at no cost, operating a parallel mission and patient pipeline that N1C's convening infrastructure directly supports.

TypeBroad incumbent
Description

Professional society defining practice standards in medical genetics, including interpretation of rare variants. Comparable as a professional membership body shaping standards and guidelines in genetics, though ACMG focuses on clinical genetics broadly rather than individualized therapy development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

N=1 Collaborative

Individualized Medicine Professional Societyn1collaborative.org

N=1 Collaborative is a 2021-founded nonprofit professional society convening researchers, clinicians, patients, regulators, and industry to advance individualized genomic medicines for ultra-rare diseases via its Connections platform, Gene Registry, workgroups, and annual meeting.

What N=1 Collaborative does

N=1 Collaborative (N1C) is a 501(c)-style nonprofit professional society founded in 2021 and headquartered in Somerville, Massachusetts, that serves as the convening body for the individualized genomic medicine field targeting ultra-rare and neurogenetic diseases. The organization operates the Connections platform as its central digital hub, complemented by specialized tools and programs including the Gene Registry (catalog of individualized therapy programs, marketed gene therapies, and assessed variants), N1C VARIANT (eligibility assessment tool for antisense oligonucleotide treatment), the Donated Resource Center, a Seminar Series, the 'Fireside Chats in Individualized Medicine' podcast, eight cross-sector workgroups (Patient Identification, Preclinical Design, Manufacturing, Institutional Implementation, Clinical Outcomes, Regulatory, Data Coordination, and Access & Funding), and an Annual Meeting. Founding support came from the Oligonucleotide Therapeutics Society N-of-1+ Taskforce and the Chan Zuckerberg Initiative, with a founding committee led by Dr. Tim Yu (designer of milasen, the first individualized ASO) and Julia Vitarello (Mila's mother).

N1C monetizes through three streams: (1) recurring membership fees that unlock exclusive Connections spaces, patient and research community engagement, virtual streaming of the Annual Meeting, and recording access; (2) sponsorships and the structured Corporate Alliance program, which let mission-aligned companies co-create shared infrastructure; and (3) tiered Annual Meeting registration ($295 industry, $180 academic/nonprofit, $120 trainee, free for parents and families). Membership pricing is gated behind platform registration and is not publicly disclosed. Customer segments span five stakeholder groups — researchers and drug developers, clinicians, patients/families/advocates (primary), plus industry/corporate partners and regulators (secondary) — with no single segment generating concentrated revenue.

The organization has facilitated treatment of more than 80 patients with over 30 individualized ASOs since the milasen precedent, and in 2025 the first personalized CRISPR-based therapy was designed, approved, and delivered in six months. Strategic positioning has been reinforced by participation in the One to Millions global public-private initiative (with Critical Path Institute, n-Lorem Foundation, Mila's Miracle Foundation, and Boston Children's Hospital, announced March 2026) and active alignment with the FDA's Plausible Mechanism Framework and the UK's rare therapies guidance. Nicole Nolen, the organization's first hire in 2022, was appointed Executive Director in June 2026, marking a transition from founder-led to executive-managed operations.

N=1 Collaborative firmographics

Firmographics
Name
N=1 Collaborative
Legal name
N=1 Collaborative
Website
https://n1collaborative.org
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
N=1 Collaborative is a 2021-founded nonprofit professional society convening researchers, clinicians, patients, regulators, and industry to advance individualized genomic medicines for ultra-rare diseases via its Connections platform, Gene Registry, workgroups, and annual meeting.
Ownership category
akta.pro rank

N=1 Collaborative industry classification

Industry
Product category
Individualized Medicine Professional Society
NAICS
Professional Organizations (81392)
SIC
Services-Membership Organizations (8600)
akta.pro industry
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)

Keywords

  • Individualized genomic medicine
  • Antisense oligonucleotide therapies
  • Rare disease therapeutics
  • Precision medicine collaboration
  • Community convening platform

Where N=1 Collaborative is headquartered

Location

Headquarters

HQ city
Somerville
HQ country
United States
HQ region
North America

Markets served

N=1 Collaborative business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Membership Fees: N1C membership provides access to exclusive platform spaces, patient and research community engagement, virtual streaming for annual meetings, recording access, and direct messaging. Membership directly supports the collective mission of advancing individualized medicines.
  2. Sponsorships: Mission-aligned organizations sponsor N1C programs including the Connections platform, annual meetings, and seminar series. Sponsorship supports N1C's ability to convene stakeholders, develop shared resources, and advance infrastructure for individualized medicine.
  3. Conference Registration: Annual meeting generates revenue through tiered registration fees: Industry ($295), Academic & Nonprofit ($180), Trainee ($120), with Parents & Families attending free.

Pricing tiers

ModelBillingPrice
OtherOne timeIndustry registration for 2026 Annual Meeting
OtherOne timeAcademic & Nonprofit registration for 2026 Annual Meeting
OtherOne timeTrainee registration for 2026 Annual Meeting
OtherOne timeParents & Families registration for 2026 Annual Meeting

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

N=1 Collaborative product offering

Product offering

Core offering

N=1 Collaborative (N1C) is a global nonprofit professional society and convening organization that serves as the professional home for interventional genetics and individualized medicine for ultra-rare diseases. It operates the Connections virtual community platform and delivers programs including eight multidisciplinary workgroups, a seminar series, a podcast, an annual meeting, the Gene Registry data resource, the Donated Resource Center, and the N1C VARIANT eligibility assessment tool, building shared infrastructure across knowledge, resources, and data for the individualized medicine ecosystem.

Product overview

N=1 Collaborative (N1C) is a global community organization serving as the professional home for interventional genetics. Rather than a unified software product, N1C operates as a platform-plus-programs organization offering the Connections community platform as its central hub, complemented by specialized tools (N1C VARIANT for eligibility assessment, Gene Registry for therapy programs), resource programs (Donated Resource Center), educational programming (Seminar Series, Podcast), collaborative workgroups (eight cross-sector groups), and an Annual Meeting. The portfolio is held together by the Connections platform, which serves as the primary engagement and resource-sharing portal for the individualized medicine ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

  • Connections Platform N1C's virtual community platform for open discussion, resource sharing, collaboration, and problem solving among researchers, clinicians, patients, advocates, and industry partners developing individualized genomic medicines.
  • N1C VARIANT Variant Assessments Towards Eligibility for Antisense Oligonucleotide Treatment - tools and guidance to support eligibility assessment for individualized therapies, representing a step toward standardized approaches to evaluating treatment eligibility.
  • Gene Registry Global catalog of individualized therapy programs, marketed gene therapies, and assessed variants designed to increase visibility and coordination across efforts, connecting researchers, clinicians, and patient communities.
  • Donated Resource Center Mobilizes in-kind goods and services to support individualized therapy efforts for patients with urgent needs by coordinating contributions across the ecosystem.
  • Fireside Chats in Individualized Medicine Podcast featuring conversations with leaders and emerging voices across the individualized medicine ecosystem, exploring technical strategy and evolving approaches in interventional genetics.
  • N1C Workgroups Eight multidisciplinary workgroups (Patient Identification, Preclinical Design, Manufacturing, Institutional Implementation, Clinical Outcomes, Regulatory, Data Coordination, and Access & Funding) that develop practical tools and standards including consensus guidelines, publications, and illustrated examples.
  • Seminar Series Ongoing virtual sessions bringing together experts across research, clinical care, and patient advocacy, covering technical insights, case studies, lessons learned, and systems-level challenges.
  • N1C Annual Meeting 2026 Annual conference titled 'Individual Journeys, Shared Discoveries: Partnering for Progress in Individualized Medicine' held October 10, 2026 in Denver, CO, bringing together the rare disease and individualized medicine community for shared learning and collaboration.

Quantifiable outcome

  • More than 80 patients treated with over 30 different individualized ASOs - demonstrating the field's progression from proof-of-concept to clinical reality
  • +2 more outcomes

Companies that use N=1 Collaborative

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

N=1 Collaborative technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

N=1 Collaborative partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and founding.

  • Critical Path Institute (C-Path)coreStrategic or Co-development Partner · 26 March 2026C-Path and N1C are founding partners in the One to Millions global public-private initiative to enable scalable development of advanced individualized therapies. The initiative leverages C-Path's regulatory-grade centralized data platform to support evidence generation, regulatory decision-making, and scalable development pathways for ASOs, gene therapies, RNA-based treatments, and genome editing for ultra-rare diseases.
  • n-Lorem FoundationcoreStrategic or Co-development Partner · 26 March 2026n-Lorem Foundation is a founding member of the One to Millions initiative alongside N1C and C-Path. The foundation focuses on developing individualized antisense oligonucleotide therapies for patients with nano-rare genetic diseases, providing experimental medicines at no cost.
  • Mila's Miracle FoundationcoreStrategic or Co-development Partner · 26 March 2026Mila's Miracle Foundation is a founding member of the One to Millions initiative. Founded by Julia Vitarello (Mila's mother), the foundation advocates for and supports the development of individualized medicines for ultra-rare diseases, inspired by the milasen case that pioneered the field.
  • Boston Children's HospitalcoreStrategic or Co-development Partner · 26 March 2026Boston Children's Hospital is a participant in the One to Millions initiative, contributing clinical expertise and research capabilities to the effort to accelerate individualized therapy development for ultra-rare diseases.
  • FDAcoreOthers · 26 March 2026The FDA provides regulatory framework support through initiatives including the Plausible Mechanism Framework and Rare Disease Evidence Principles. These frameworks enable scalable development pathways for individualized therapies and are referenced in the One to Millions initiative. FDA's 2021 individualized ASO guidance established foundational regulatory pathways.
  • Oligonucleotide Therapeutics Society N-of-1+ TaskforcefoundingStrategic or Co-development Partner · 1 January 2021The Oligonucleotide Therapeutics Society's N-of-1+ Taskforce provided founding support for N1C's creation in 2021. This scientific society brought together leaders who helped establish N1C as the professional home for the individualized medicine field.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

N=1 Collaborative competitors and assessment

Company assessment

Broad incumbents

  • National Organization for Rare Disorders (NORD): Largest US rare disease umbrella organization serving patients, advocacy groups, and industry. Comparable as a broad convening and advocacy organization covering rare diseases, though NORD operates at a much larger scale and addresses a wider scope than N1C's individualized-medicine focus.
  • Genetic Alliance: Long-established nonprofit advancing genetic health through data platforms (including Platform for Engaging Everyone Responsibly, or PEER) and a network of disease advocacy organizations. Comparable as a community-and-data infrastructure builder for genetic and rare disease communities.
  • EveryLife Foundation for Rare Diseases: Advocacy and policy organization for the rare disease community, focused on accelerating science, policy, and regulatory pathways. Comparable as a US-based rare disease ecosystem convener engaging FDA, NIH, and Congress on drug development issues parallel to N1C's regulatory work.
  • Personalized Medicine Coalition: Cross-stakeholder coalition advancing the adoption of personalized medicine across policy, clinical practice, and industry. Comparable to N1C as a convening platform for personalized medicine, but operates at a broader policy level across all personalized medicine rather than focusing on individualized n-of-1 therapies.
  • American College of Medical Genetics and Genomics (ACMG): Professional society defining practice standards in medical genetics, including interpretation of rare variants. Comparable as a professional membership body shaping standards and guidelines in genetics, though ACMG focuses on clinical genetics broadly rather than individualized therapy development.

Direct peers

  • Mila's Miracle Foundation: Founding One to Millions partner. Founded by Julia Vitarello (also an N1C founder), the foundation is anchored on the milasen case that pioneered individualized ASOs and advocates for ultra-rare patient access — closely aligned with N1C's mission and leadership.
  • Critical Path Institute (C-Path): Co-founding partner of One to Millions with N1C. C-Path provides regulatory-grade data infrastructure and works across multiple rare disease consortia, making it the closest peer in terms of public-private convening and regulatory science infrastructure for individualized therapies.
  • n-Lorem Foundation: Founding partner in the One to Millions initiative and core collaborator with N1C. n-Lorem develops individualized ASO therapies for nano-rare patients at no cost, operating a parallel mission and patient pipeline that N1C's convening infrastructure directly supports.

Emerging players

  • Chan Zuckerberg Initiative Rare As One Network: CZI's Rare As One Network funds rare disease patient-led organizations to accelerate research and treatments. Comparable as a CZI-backed ecosystem builder in rare disease; CZI also funded N1C's founding, making it both a funder and a parallel community-building initiative.

Regional players

  • FAST (Foundation for Angelman Syndrome Therapeutics): Patient-founded research foundation focused on a single ultra-rare disease. Comparable in mission orientation (patient-driven infrastructure for an ultra-rare condition advancing individualized therapeutics) but operates with a different scale and disease-specific scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

N=1 Collaborative social profiles

Digital presence

N=1 Collaborative financial estimates

Financial estimate

Revenue estimate

Valuation estimate

N=1 Collaborative leadership team

Management profile

Number of profiles

Profiles2 records

N=1 Collaborative funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

N=1 Collaborative M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about N=1 Collaborative

What does N=1 Collaborative do?

N=1 Collaborative (N1C) is a global nonprofit professional society and convening organization that serves as the professional home for interventional genetics and individualized medicine for ultra-rare diseases. It operates the Connections virtual community platform and delivers programs including eight multidisciplinary workgroups, a seminar series, a podcast, an annual meeting, the Gene Registry data resource, the Donated Resource Center, and the N1C VARIANT eligibility assessment tool, building shared infrastructure across knowledge, resources, and data for the individualized medicine ecosystem.

Is N=1 Collaborative a public or private company?

N=1 Collaborative is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was N=1 Collaborative founded?

N=1 Collaborative was founded in 2021. It employs 11 to 50 people.

Where is N=1 Collaborative based?

N=1 Collaborative is headquartered in Somerville, United States, in the North America region.

How does N=1 Collaborative make money?

Three revenue lines are on record. Membership Fees are the primary driver. The others are sponsorships and conference Registration.

Who are N=1 Collaborative's main competitors?

Broad incumbents on record are National Organization for Rare Disorders (NORD), Genetic Alliance, EveryLife Foundation for Rare Diseases, Personalized Medicine Coalition and American College of Medical Genetics and Genomics (ACMG). Direct peers are Mila's Miracle Foundation, Critical Path Institute (C-Path) and n-Lorem Foundation. Chan Zuckerberg Initiative Rare As One Network is listed as an emerging player. FAST (Foundation for Angelman Syndrome Therapeutics) is listed as a regional player.

Does N=1 Collaborative have an API?

No public API is recorded for N=1 Collaborative.

What industry is N=1 Collaborative in?

N=1 Collaborative's product category is Individualized Medicine Professional Society. Its primary akta.pro industry code is HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 81392 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswirezmena budúcnosti individualizovanej medicíny v globálnom meradleThe Critical Path Institute (C-Path) announced the launch of the One to Millions initiative, a global public-private partnership aimed at accelerating the development of advanced therapies for highly individualized diseases such as rare genetic conditions. The initiative addresses a growing gap between rapidly advancing technologies—including antisense oligonucleotides, genome editing, gene therapies, and RNA-based treatments—and existing regulatory and reimbursement frameworks designed for population-level drugs. Founding members include n-Lorem Foundation, Mila's Miracle Foundation, and N=1 Collaborative, with the program utilizing C-Path's centralized data platform and FDA's rare disease regulatory framework to enable scalable development pathways.PR Newswirepour redessiner l'avenir de la médecine individualisée à l'échelle mondiale.The Critical Path Institute announced the launch of the global public-private initiative "One to Millions" to accelerate the development of and patient access to advanced individualized therapies such as antisense oligonucleotides, gene therapies, and RNA-based treatments. The initiative addresses gaps between existing regulatory frameworks designed for mass-market drugs and the needs of treatments targeting very small or individual patient populations. It leverages C-Path's centralized, regulatory-grade data platform and builds on the FDA's 2021 individualized ASO guidance, with participation from the n-Lorem Foundation, Mila's Miracle Foundation, and the N=1 Collaborative.STATA mother, shaped by tragedy, embarks on a mission to advance custom medicinesJulia Vitarello, whose daughter Mila died of Batten disease in 2021, is now advancing custom medicines to treat rare diseases. She helped organize the N=1 Collaborative and works on reimbursement and regulation, aiming to scale personalized drug development.